MiNK Therapeutics (INKT) Competitors $10.18 +0.32 (+3.29%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$9.86 -0.33 (-3.23%) As of 02/21/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INKT vs. TIL, LXEO, ADAP, STRO, SLN, MCRB, PBYI, CHRS, BMEA, and BDTXShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Instil Bio (TIL), Lexeo Therapeutics (LXEO), Adaptimmune Therapeutics (ADAP), Sutro Biopharma (STRO), Silence Therapeutics (SLN), Seres Therapeutics (MCRB), Puma Biotechnology (PBYI), Coherus BioSciences (CHRS), Biomea Fusion (BMEA), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Instil Bio Lexeo Therapeutics Adaptimmune Therapeutics Sutro Biopharma Silence Therapeutics Seres Therapeutics Puma Biotechnology Coherus BioSciences Biomea Fusion Black Diamond Therapeutics MiNK Therapeutics (NASDAQ:INKT) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings. Does the media refer more to INKT or TIL? In the previous week, MiNK Therapeutics had 1 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for MiNK Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.20 beat MiNK Therapeutics' score of 0.00 indicating that Instil Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Instil Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of INKT or TIL? 2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 20.6% of MiNK Therapeutics shares are owned by insiders. Comparatively, 46.5% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is INKT or TIL more profitable? MiNK Therapeutics' return on equity of 0.00% beat Instil Bio's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -189.14% Instil Bio N/A -37.44%-25.08% Which has more volatility & risk, INKT or TIL? MiNK Therapeutics has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Instil Bio has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Do analysts rate INKT or TIL? MiNK Therapeutics currently has a consensus price target of $65.00, suggesting a potential upside of 538.26%. Instil Bio has a consensus price target of $114.00, suggesting a potential upside of 415.37%. Given MiNK Therapeutics' higher probable upside, equities analysts plainly believe MiNK Therapeutics is more favorable than Instil Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Instil Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better earnings and valuation, INKT or TIL? MiNK Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$22.46M-$3.90-2.61Instil BioN/AN/A-$156.09M-$11.56-1.91 Does the MarketBeat Community favor INKT or TIL? Instil Bio received 86 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 75.00% of users gave MiNK Therapeutics an outperform vote while only 50.50% of users gave Instil Bio an outperform vote. CompanyUnderperformOutperformMiNK TherapeuticsOutperform Votes1575.00% Underperform Votes525.00% Instil BioOutperform Votes10150.50% Underperform Votes9949.50% SummaryInstil Bio beats MiNK Therapeutics on 9 of the 15 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.06M$3.12B$5.85B$9.15BDividend YieldN/A1.56%4.76%3.85%P/E Ratio-2.6110.3116.5114.19Price / SalesN/A327.11450.0276.60Price / CashN/A168.8538.0134.95Price / Book-1.953.687.644.63Net Income-$22.46M-$71.72M$3.18B$245.69M7 Day Performance7.20%-2.46%-1.95%-2.68%1 Month Performance0.83%-0.25%-0.23%-2.16%1 Year Performance9.84%-12.31%16.69%12.90% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.4726 of 5 stars$10.18+3.3%$65.00+538.3%+10.7%$39.06MN/A-2.6130News CoverageTILInstil Bio2.9407 of 5 stars$23.01-3.5%$114.00+395.4%+88.3%$150.26MN/A-1.99410News CoveragePositive NewsLXEOLexeo Therapeutics3.3573 of 5 stars$4.50+6.6%$23.80+428.9%-74.8%$148.82M$650,000.00-1.4258News CoverageADAPAdaptimmune Therapeutics2.3358 of 5 stars$0.58+0.3%$2.79+382.3%-62.7%$147.90M$60.28M-2.63490Positive NewsSTROSutro Biopharma4.2576 of 5 stars$1.79+2.9%$11.13+521.5%-61.9%$147.60M$153.73M-1.11240SLNSilence Therapeutics2.1387 of 5 stars$4.84+7.6%$45.00+829.8%-79.9%$144.86M$31.55M-3.08100MCRBSeres Therapeutics3.9958 of 5 stars$0.83-0.9%$5.08+510.5%-23.5%$142.18M$126.32M-3.62330News CoveragePBYIPuma Biotechnology3.7611 of 5 stars$2.86-1.7%$7.00+144.8%-55.5%$140.40M$235.60M5.96200Upcoming EarningsNews CoverageCHRSCoherus BioSciences3.6681 of 5 stars$1.18+1.7%$5.38+355.5%-56.9%$136.75M$257.24M-14.75330BMEABiomea Fusion3.3375 of 5 stars$3.73+3.3%$39.36+955.3%-77.4%$135.17MN/A-0.9350Positive NewsBDTXBlack Diamond Therapeutics3.3805 of 5 stars$2.37+1.3%$15.50+554.0%-53.7%$134.10MN/A-1.7890Short Interest ↓Positive News Related Companies and Tools Related Companies Instil Bio Competitors Lexeo Therapeutics Competitors Adaptimmune Therapeutics Competitors Sutro Biopharma Competitors Silence Therapeutics Competitors Seres Therapeutics Competitors Puma Biotechnology Competitors Coherus BioSciences Competitors Biomea Fusion Competitors Black Diamond Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INKT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
